In Silico screening will become a cornerstone of cardiotox testing in drug development. Clyde Biosciences’ in silico service provides confidence about ion channel measurement of drug activity.
Clyde’s In Silico Service: Modelling the Future
Clyde Biosciences has developed a computational model of electrophysiological and intracellular calcium signals in human iPS-derived cardiac cells.
Our model integrates 20 ion channels, and 4 ion pumps and exchangers, to provide a detailed quantitative description of drug effects on membrane potential and intracellular calcium signals.
This model is used as a tool to provide detail on the effects of drugs on human cardiac electrophysiology and arrhythmogenesis.
Use of in silico techniques is a cornerstone of CiPA – offering a potential index of proarrhythmic risk.
Clyde works with leading providers of iPS-CMs to develop accurate, predictive models of their cell lines. Once validated, those models can then be applied to drug candidates from biopharma companies to provide accurate in silico measurements of their ion channel actions.
Major benefits include:
- A complete picture of your compounds’ predicted effects on cardiac ion channels
- Rapid turnaround providing meaningful data within your timescales
- Placing you at the leading edge of predictive cardiac toxicology